Arcus Biosciences, Inc. Accumulated Other Comprehensive Income
Arcus Biosciences, Inc. (RCUS) had Accumulated Other Comprehensive Income of -$1.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.00M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.00M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2024-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.00M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$1.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$1.00M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $1.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | -$1.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$1.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-09-30 | -$3.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$4.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | -$4.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$7.00M 10-K · filed 2024-02-21 | |
| 2022-09-30 | -$9.80M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | -$7.24M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | -$4.66M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | -$1.00M 10-K · filed 2023-02-28 | -$1.26M 10-K · filed 2022-02-23 |
| 2021-09-30 | -$92.00K 10-Q · filed 2021-11-08 | |
| 2021-06-30 | -$46.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | -$2.00K 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $44.00K 10-K · filed 2022-02-23 | |
| 2020-09-30 | $81.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $144.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $288.00K 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $64.00K 10-K · filed 2021-02-25 | |
| 2019-09-30 | $53.00K 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $113.00K 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $29.00K 10-Q · filed 2019-05-02 | |
| 2018-12-31 | -$107.00K 10-K · filed 2020-03-05 | |
| 2018-09-30 | -$108.00K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$83.00K 10-Q · filed 2018-08-06 | |
| 2018-03-31 | -$97.00K 10-Q · filed 2018-05-09 | |
| 2017-12-31 | -$42.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |